Concepts (184)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brenner Tumor | 3 | 2021 | 3 | 1.830 |
Why?
|
| Neoplasms, Complex and Mixed | 2 | 2020 | 43 | 1.270 |
Why?
|
| Ovarian Neoplasms | 8 | 2022 | 4638 | 1.240 |
Why?
|
| Ovary | 2 | 2021 | 668 | 1.150 |
Why?
|
| Fallopian Tube Neoplasms | 3 | 2022 | 153 | 0.990 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2022 | 19 | 0.880 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2022 | 23 | 0.870 |
Why?
|
| Pregnancy, Ectopic | 1 | 2022 | 30 | 0.870 |
Why?
|
| Uterine Neoplasms | 3 | 2022 | 545 | 0.850 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 144 | 0.830 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 487 | 0.810 |
Why?
|
| Herpesviridae Infections | 1 | 2023 | 175 | 0.810 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2022 | 108 | 0.800 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2020 | 35 | 0.760 |
Why?
|
| Granulosa Cell Tumor | 1 | 2020 | 77 | 0.730 |
Why?
|
| Appendiceal Neoplasms | 1 | 2022 | 234 | 0.710 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2018 | 7 | 0.640 |
Why?
|
| Cell Lineage | 1 | 2021 | 668 | 0.640 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2022 | 519 | 0.620 |
Why?
|
| Immunohistochemistry | 8 | 2021 | 7548 | 0.600 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2021 | 436 | 0.550 |
Why?
|
| Endodermal Sinus Tumor | 1 | 2016 | 47 | 0.540 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2017 | 486 | 0.530 |
Why?
|
| PAX8 Transcription Factor | 4 | 2016 | 55 | 0.530 |
Why?
|
| Endometrial Neoplasms | 4 | 2023 | 1341 | 0.530 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2014 | 34 | 0.510 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2013 | 14 | 0.480 |
Why?
|
| Biomarkers, Tumor | 10 | 2021 | 10331 | 0.450 |
Why?
|
| Salpingo-oophorectomy | 3 | 2021 | 50 | 0.390 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2011 | 103 | 0.380 |
Why?
|
| Alphapapillomavirus | 1 | 2011 | 171 | 0.340 |
Why?
|
| Endometriosis | 2 | 2024 | 214 | 0.290 |
Why?
|
| Female | 25 | 2024 | 141928 | 0.270 |
Why?
|
| Endometrium | 4 | 2023 | 470 | 0.270 |
Why?
|
| Diagnosis, Differential | 4 | 2022 | 4744 | 0.260 |
Why?
|
| Epithelium | 3 | 2023 | 720 | 0.260 |
Why?
|
| PAX2 Transcription Factor | 2 | 2014 | 43 | 0.250 |
Why?
|
| Paired Box Transcription Factors | 2 | 2014 | 134 | 0.240 |
Why?
|
| Middle Aged | 13 | 2023 | 86204 | 0.240 |
Why?
|
| GATA3 Transcription Factor | 2 | 2014 | 146 | 0.240 |
Why?
|
| Fallopian Tubes | 2 | 2022 | 119 | 0.240 |
Why?
|
| Biopsy | 4 | 2021 | 3443 | 0.230 |
Why?
|
| Proteogenomics | 1 | 2023 | 87 | 0.220 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2022 | 51 | 0.220 |
Why?
|
| Smad Proteins | 1 | 2023 | 88 | 0.220 |
Why?
|
| Epithelioid Cells | 1 | 2022 | 43 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 980 | 0.210 |
Why?
|
| Aminopyridines | 1 | 2024 | 212 | 0.210 |
Why?
|
| Mucous Membrane | 1 | 2022 | 271 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinase 2 | 1 | 2021 | 14 | 0.200 |
Why?
|
| Humans | 27 | 2024 | 261506 | 0.200 |
Why?
|
| Mucins | 1 | 2022 | 285 | 0.200 |
Why?
|
| Pathologists | 1 | 2021 | 91 | 0.190 |
Why?
|
| Forkhead Box Protein L2 | 1 | 2020 | 17 | 0.190 |
Why?
|
| Uterus | 2 | 2023 | 678 | 0.190 |
Why?
|
| Adult | 11 | 2022 | 77950 | 0.180 |
Why?
|
| Hysterectomy | 2 | 2021 | 611 | 0.180 |
Why?
|
| Pyrroles | 1 | 2024 | 576 | 0.180 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2021 | 268 | 0.180 |
Why?
|
| Neoplasms | 2 | 2023 | 15193 | 0.170 |
Why?
|
| Metaplasia | 1 | 2021 | 383 | 0.170 |
Why?
|
| Metformin | 1 | 2023 | 378 | 0.170 |
Why?
|
| Infertility, Female | 1 | 2021 | 217 | 0.170 |
Why?
|
| Embryo Implantation | 1 | 2021 | 278 | 0.170 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2018 | 18 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4892 | 0.170 |
Why?
|
| Squamous Intraepithelial Lesions of the Cervix | 1 | 2018 | 15 | 0.170 |
Why?
|
| Aged | 9 | 2022 | 70117 | 0.170 |
Why?
|
| Smad2 Protein | 1 | 2019 | 89 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2011 | 5437 | 0.160 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 1742 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 402 | 0.160 |
Why?
|
| Smad3 Protein | 1 | 2019 | 129 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2021 | 534 | 0.160 |
Why?
|
| Gastritis | 1 | 2021 | 373 | 0.160 |
Why?
|
| Papanicolaou Test | 1 | 2018 | 141 | 0.160 |
Why?
|
| Gastric Mucosa | 1 | 2021 | 613 | 0.150 |
Why?
|
| Electrosurgery | 1 | 2017 | 28 | 0.150 |
Why?
|
| Infertility | 1 | 2019 | 123 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2020 | 353 | 0.140 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2016 | 323 | 0.140 |
Why?
|
| Peritoneum | 1 | 2017 | 150 | 0.140 |
Why?
|
| Omentum | 1 | 2017 | 96 | 0.140 |
Why?
|
| Steroidogenic Factor 1 | 1 | 2016 | 39 | 0.140 |
Why?
|
| Leiomyoma | 1 | 2017 | 145 | 0.140 |
Why?
|
| Adnexal Diseases | 1 | 2016 | 30 | 0.140 |
Why?
|
| Dermatofibrosarcoma | 1 | 2016 | 72 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 3976 | 0.130 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2017 | 219 | 0.130 |
Why?
|
| Progesterone | 1 | 2017 | 513 | 0.130 |
Why?
|
| Pregnancy | 3 | 2022 | 7573 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 2283 | 0.120 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 236 | 0.120 |
Why?
|
| Proteomics | 1 | 2021 | 1380 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 2014 | 429 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 1756 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 2045 | 0.100 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2011 | 97 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2011 | 64 | 0.100 |
Why?
|
| Keratins | 1 | 2011 | 330 | 0.100 |
Why?
|
| Adenoma | 1 | 2016 | 716 | 0.100 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2011 | 133 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2014 | 5270 | 0.090 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1037 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2011 | 476 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2011 | 829 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2021 | 37905 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2011 | 694 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2023 | 4078 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 2488 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2011 | 671 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2013 | 1987 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 29902 | 0.080 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 551 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 3981 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8873 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 13658 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 15179 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2011 | 1664 | 0.060 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2011 | 1105 | 0.060 |
Why?
|
| Smad5 Protein | 1 | 2021 | 27 | 0.050 |
Why?
|
| Activin Receptors, Type II | 1 | 2021 | 38 | 0.050 |
Why?
|
| Smad1 Protein | 1 | 2021 | 35 | 0.050 |
Why?
|
| Phosphotransferases | 1 | 2021 | 84 | 0.050 |
Why?
|
| Animals | 4 | 2023 | 59536 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2021 | 5710 | 0.050 |
Why?
|
| Health Care Surveys | 1 | 2021 | 430 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2024 | 661 | 0.040 |
Why?
|
| Time Factors | 1 | 2013 | 12926 | 0.040 |
Why?
|
| beta Catenin | 1 | 2023 | 688 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4654 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 3230 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 3552 | 0.040 |
Why?
|
| Homeostasis | 1 | 2023 | 950 | 0.040 |
Why?
|
| Role | 1 | 2017 | 48 | 0.040 |
Why?
|
| Cell Survival | 1 | 2024 | 3045 | 0.040 |
Why?
|
| Estrogens | 1 | 2021 | 751 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 1000 | 0.040 |
Why?
|
| Sertoli Cell Tumor | 1 | 2016 | 12 | 0.040 |
Why?
|
| Neurofibroma | 1 | 2016 | 31 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2017 | 198 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9244 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2023 | 2054 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 34495 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 173 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 860 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7226 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2021 | 1152 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 358 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 309 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 268 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2024 | 11965 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 387 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 493 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 1217 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1363 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1392 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 838 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2020 | 2218 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1026 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2013 | 32848 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1859 | 0.030 |
Why?
|
| Young Adult | 1 | 2011 | 21445 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 3536 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 509 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3101 | 0.020 |
Why?
|
| Observer Variation | 1 | 2011 | 671 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 3639 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 7222 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 4053 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 6150 | 0.020 |
Why?
|
| Male | 2 | 2021 | 123000 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5112 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 6682 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 5159 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 7551 | 0.020 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6009 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17523 | 0.010 |
Why?
|
| Prognosis | 1 | 2017 | 21713 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 10035 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 15694 | 0.010 |
Why?
|